What is Isabl?
Founded in 2020, Isabl operates at the intersection of biotechnology and advanced data analytics. The company provides a comprehensive precision oncology test that synthesizes whole genome and transcriptome sequencing to offer a holistic view of a patient's cancer. Unlike traditional diagnostic methods that may focus on isolated mutations, Isabl's platform captures the broader genomic landscape, enabling oncologists to identify rare therapeutic targets and optimize treatment pathways. This market position is critical, as the demand for high-fidelity diagnostic tools continues to rise in response to the growing complexity of targeted cancer therapies and immunotherapy applications.
How much funding has Isabl raised?
Isabl has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2022): $3M with participation from Two Sigma Ventures, BoxOne Ventures, and Y Combinator
Key Investors in Isabl
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power, with a specific focus on breakthrough therapies and data-driven healthcare innovation.
BoxOne Ventures
BoxOne Ventures Inc is a strategic investment firm that provides capital and operational support to emerging companies, focusing on high-growth sectors including financial technology and specialized healthcare services.
Y Combinator
Y Combinator is a premier startup accelerator that provides seed funding and mentorship to early-stage companies, helping them scale their operations and connect with a global network of investors.
What's next for Isabl?
With this major enterprise-level funding, Isabl is poised to scale its operational infrastructure and expand its clinical footprint. The company is expected to focus on enhancing its diagnostic throughput and deepening its integration with hospital information systems to streamline the delivery of genomic reports. Furthermore, the capital will likely support ongoing research and development efforts aimed at refining the platform's predictive capabilities, potentially expanding its utility into new oncology indications. As the firm transitions from its initial development phase to a broader commercial rollout, the focus will remain on establishing clinical utility and securing partnerships with leading cancer centers to solidify its role as a standard-bearer in the precision medicine ecosystem.
See full Isabl company page
